Michelle Aguirre-MacKenzie

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults”.

Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults

Clinical Infectious Diseases(2023)10.1093/cid/ciad693

N/A

0.671DataRank · unranked

16 citations

Ken Liu, Édouard Lhomme, Julie Blie, John McCullough, Matthew Onorato +90 more

Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases

Nature Communications(2024)10.1038/s41467-024-51453-z

N/A

0.596DataRank · unranked

19 citations

Édouard Lhomme, Mélanie Huchon, Emile Foucat, Marion Bérerd-Camara, Lydia Guillaumat +94 more

Evaluation of waning of IgG antibody responses after rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial

Emerging Microbes & Infections(2024)10.1080/22221751.2024.2432353

N/A

0.251DataRank · unranked

4 citations

Marie Alexandre, Mélanie Prague, Abdoul Habib Béavogui, Seydou Doumbia, Mark Kieh +94 more